Profesores del Programa
Iván Plaza Menacho
Centro Nacional de Investigaciones Oncológicas, CNIOHead of the Protein Phosphorylation and Cancer Group
E1 L1
Tesis dirigidas:
Iván Plaza Menacho is the head of the Protein Phosphorylation and Cancer Group at the Spanish National Cancer Institute (CNIO). He recently joined CNIO to start a highly competitive lab focused on structure-function studies of protein kinases and structure-based drug discovery. Iván Plaza-Menacho obtained his BSc degree by the University of Cádiz (2001). He did his PhD studies (2002-2006) with Prof. Robert Hofstra as a Ubbo-Emmius and Groningen Institute for Drug Exploration (GUIDE) scholar at the University of Groningen working on the characterization of the RET proto-oncogene signalling. In 2006 he moved to the Institute of Cancer Research (London) with Prof. Clare Isacke to work on RET signalling in breast cancer under an International Postdoctoral Fellowship (Ministerio de Educación y Ciencia of Spain). In 2009 he moved to the London Research Institute with a CRUK postdoctoral fellowship to focus on structure-function studies on RET kinase activation and oncogenic de-regulation, and at the same time continued his work on RET signaling in breast cancer and endocrine resistance under an AICR funded project. After a 2-year period (March 2015 to April 2017) working on the structural and functional characterization of histidine kinases signalling in the Biozentrum University of Basel, Iván moved to Madrid to start the Protein Phosphorylation and Cancer Group at CNIO. Iván been the recipient of prestigious CRUK-postdoctoral, Marie Curie-WHRI and Ramón y Cajal fellowships
Claves / Resumen
Iván Plaza Menacho is the head of the Protein Phosphorylation and Cancer Group at the Spanish National Cancer Institute (CNIO). He recently joined CNIO to start a highly competitive lab focused on structure-function studies of protein kinases and structure-based drug discovery. Iván Plaza-Menacho obtained his BSc degree by the University of Cádiz (2001). He did his PhD studies (2002-2006) with Prof. Robert Hofstra as a Ubbo-Emmius and Groningen Institute for Drug Exploration (GUIDE) scholar at the University of Groningen working on the characterization of the RET proto-oncogene signalling. In 2006 he moved to the Institute of Cancer Research (London) with Prof. Clare Isacke to work on RET signalling in breast cancer under an International Postdoctoral Fellowship (Ministerio de Educación y Ciencia of Spain). In 2009 he moved to the London Research Institute with a CRUK postdoctoral fellowship to focus on structure-function studies on RET kinase activation and oncogenic de-regulation, and at the same time continued his work on RET signaling in breast cancer and endocrine resistance under an AICR funded project. After a 2-year period (March 2015 to April 2017) working on the structural and functional characterization of histidine kinases signalling in the Biozentrum University of Basel, Iván moved to Madrid to start the Protein Phosphorylation and Cancer Group at CNIO. Iván been the recipient of prestigious CRUK-postdoctoral, Marie Curie-WHRI and Ramón y Cajal fellowships
Enlaces curriculares
Publicaciones
- 2023 - J Adv Res (ver indicadores de calidad)
Shehata MA, Contreras J, Martín-Hurtado A, Froux A, Mohamed HT, El-Sherif AA, Plaza-Menacho I. Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability. J Adv Res. 2023 Mar;45:87-100. doi: 10.1016/j.jare.2022.05.004. Epub 2022 May 17. PMID: 35595215; PMCID: PMC10006619. - 2020 - Proc Natl Acad Sci U S A (ver indicadores de calidad)
Dubey BN, Agustoni E, Böhm R, Kaczmarczyk A, Mangia F, von Arx C, Jenal U, Hiller S, Plaza-Menacho I, Schirmer T. Hybrid histidine kinase activation by cyclic di-GMP-mediated domain liberation. Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1000-1008. doi: 10.1073/pnas.1911427117. Epub 2019 Dec 27. PMID: 31882446; PMCID: PMC6969517. - 2018 - Endocr Relat Cancer (ver indicadores de calidad)
Redaelli S, Plaza-Menacho I, Mologni L. Novel targeted therapeutics for MEN2. Endocr Relat Cancer. 2018 Feb;25(2):T53-T68. doi: 10.1530/ERC-17-0297. PMID: 29348306. - 2018 - Endocr Relat Cancer (ver indicadores de calidad)
Plaza-Menacho I. Structure and function of RET in multiple endocrine neoplasia type 2. Endocr Relat Cancer. 2018 Feb;25(2):T79-T90. doi: 10.1530/ERC-17-0354. Epub 2017 Nov 24. PMID: 29175871. - 2016 - Cell Rep (ver indicadores de calidad)
Plaza-Menacho I, Barnouin K, Barry R, Borg A, Orme M, Chauhan R, Mouilleron S, Martínez-Torres RJ, Meier P, McDonald NQ. RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements. Cell Rep. 2016 Dec 20;17(12):3319-3332. doi: 10.1016/j.celrep.2016.11.061. PMID: 28009299; PMCID: PMC5199340. - 2016 - Sci Adv (ver indicadores de calidad)
Dubey BN, Lori C, Ozaki S, Fucile G, Plaza-Menacho I, Jenal U, Schirmer T. Cyclic di-GMP mediates a histidine kinase/phosphatase switch by noncovalent domain cross-linking. Sci Adv. 2016 Sep 16;2(9):e1600823. doi: 10.1126/sciadv.1600823. PMID: 27652341; PMCID: PMC5026420. - 2014 - Cell Signal (ver indicadores de calidad)
Plaza-Menacho I, Mologni L, McDonald NQ. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy. Cell Signal. 2014 Aug;26(8):1743-52. doi: 10.1016/j.cellsig.2014.03.032. Epub 2014 Apr 3. PMID: 24705026. - 2014 - Mol Cell (ver indicadores de calidad)
Plaza-Menacho I, Barnouin K, Goodman K, Martínez-Torres RJ, Borg A, Murray-Rust J, Mouilleron S, Knowles P, McDonald NQ. Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans. Mol Cell. 2014 Mar 6;53(5):738-51. doi: 10.1016/j.molcel.2014.01.015. Epub 2014 Feb 20. PMID: 24560924; PMCID: PMC3988870. - 2013 - Mol Cell Endocrinol (ver indicadores de calidad)
Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol. 2013 Sep 5;377(1-2):1-6. doi: 10.1016/j.mce.2013.06.025. Epub 2013 Jun 27. PMID: 23811235. - 2013 - Cancer Res (ver indicadores de calidad)
Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6. PMID: 23650283; PMCID: PMC3686594.
Ver todos los profesores del Programa
Limitación de responsabilidad.
El contenido de esta Web, en todo lo relativo a normativas o procedimientos relacionados con el Programa de Doctorado, es un resumen sencillo y reorganizado de información extraída e interpretada de otras fuentes. Los contenidos no implican ninguna responsabilidad personal o institucional y no tienen valor como referencia normativa. Toda la documentación oficial de referencia está recogida en la Web de la Escuela de Doctorado de la UAH.